Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A1. ANTICOAGULATION CLINICS | |||||
|
(401) ANALYSIS OF PHARMACIST INTERVENTIONS WITHIN A DIRECT ORAL ANTICOAGULATION MANAGEMENT PROTOCOL Clara J Nickel2, Anne E Rose1. 1University of Wisconsin Health, Madison, WI, USA 2University of Wisconsin School of Pharmacy, Madison, WI, USA |
||||
A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION | |||||
|
(402) CHARACTERIZATION OF THE ENDOTHELIAL CELL SUBPOPULATIONS MARKED BY TEK AND CDH5 PROMOTER DRIVEN CRE EXPRESSION IN DIFFERENT MOUSE STRAINS David Svilar1,2, Audrey Cleuren1,3, David Siemieniak1, David Ginsburg1,2,4,5. 1Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA 2Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA 3Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA 4Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA 5Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA |
||||
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(403) ELECTRONIC MEDICAL RECORD INTERVENTIONS IN REDUCING INAPPROPRIATE TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA: EXPERIENCE IN A LARGE TEACHING HOSPITAL SYSTEM Mukul Singal1,2, Soon K. Low3,4, Peter A. Kouides5,6, Maura Wychowski6, Ronald L. Sham5,6. 1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA 2Hematology and Oncology Fellowship, Rochester General Hospital, Rochester, NY, USA 3Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, USA 4Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA 5Mary M. Gooley Hemophilia and Thrombosis Center, Rochester, NY, USA 6Department of Hematology and Oncology, Rochester General Hospital, Rochester, NY, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(404) ARTIFICIAL INTELLIGENCE AND VENOUS THROMBOEMBOLISM: TALKING TO THE EXPERTS Anuranita Gupta1, Barbara D Lam2,13, Sabrina Zerbey2, William Robertson3, Rachel P Rosovsky4, Leslie Lake5, Laura Dodge6, Alys Adamski7, Nimia Reyes7, Karon Abe7, Ioannis Vlachos8, Jeffrey I Zwicker9,10, Mara Schonberg11, Rushad Patell12. 1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 2Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center,, Boston, MA 3Weber State University, Ogden, UT 4Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 5National Blood Clot Alliance, Philadelphia, PA 6Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 7Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA 8Department of Pathology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 9Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY 10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY 11Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA 12Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 13Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Boston, MA |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(405) T-HLPER CYTOKINE INTERACTIONS WITH BAFF IN THE FACTOR VIII IMMUNE RESPONSE Tammi L. Briscoe1, Mostafa A. Shaheen1, Bhavya S. Doshi1,2. 1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA |
||||
|
(406) SURGICAL AND PROCEDURAL OUTCOMES FOR PATIENTS WITH FACTOR VIII DEFICIENCY TAKING EMICIZUMAB PROPHYLACTICALLY: A REGIONAL APPROACH TO DATA COLLECTION AND ANALYSIS Janice Kuhn1, Butler Regina2, Mailie-Howell Lisa2, Druzgal Colleen3, Sennett Margy3. 1Virginia Commonwealth University, Richmond, VA, USA 2Children's Hospital of Philadelphia, Philadelphila, PA, USA 3University of Virginia, Charlottesville, VA, USA |
||||
|
(407) TRENDS OF ACUTE ISCHEMIC STROKE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A DECADE STUDY Ayobami Olafimihan1, Stanley ozogbo2, Praise fawehinmi3, Gbolahan Olatunji4, Emmanuel Kokori4, Aderinto Nicholas5, Ekrem Turk1, Lina George1, Shaka Hafeez1. 1John H. Stroger Jr Hospital, Chicago, IL, USA 2Mercy Health- St. Elizabeth Hospital, Youngstown, OH, USA 3Southern Illinois University Edwardsville, Chicago, IL, USA 4University of Ilorin, Ilorin, Nigeria 5Ladoke Akintola University of Technology, Ogbomosho, Nigeria |
||||
|
(408) SUSTAINED EFFICACY AND SAFETY 3 YEARS FOLLOWING INFUSION WITH ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B IN THE PHASE 3 HOPE-B CLINICAL TRIAL Steven W. Pipe1, Paul van der Valk2, Peter Verhamme3, Peter Kampmann4, Frank Leebeek5, Michiel Coppens6, Nigel Key7, Nathan Visweshwar8, Guy Young9, Richard Lemons10, Robert Klamroth11, Niamh O'Connell12, Sandra le Quellec13, Paul Monahan13, Cedric Hermans14. 1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA 2Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands 3Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium 4Rigshospitalet, Copenhagen, Denmark 5Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands 6Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands 7University of North Carolina, Chapel Hill, NC, USA 8University of South Florida, Tampa, FL, USA 9University of Southern California Keck School of Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA 10University of Utah, Salt Lake City, UT, USA 11Vivantes Klinikum im Friedrichshain, Berlin, Germany 12National Coagulation Centre, St. James’s Hospital, Dublin, Ireland 13CSL Behring, King of Prussia, PA, USA 14Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium |
||||
|
(409) LONG-TERM SAFETY AND EFFICACY OF FITUSIRAN PROPHYLAXIS IN A PHASE 1/2 OPEN-LABEL EXTENSION STUDY IN PEOPLE WITH MODERATE OR SEVERE HEMOPHILIA A OR B Steven W. Pipe1, Toshko Lissitchkov2, Sarah Mangles3, Pencho Georgiev4, Erin Feng5, Laurel A. Menapace6, Salim Kichou7, Shauna Andersson6, Marek Demissie6, Margaret Ragni8. 1University of Michigan, Ann Arbor, MI, USA 2Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria 3Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom 4University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria 5Sanofi, Shanghai, China 6Sanofi, Cambridge, MA, USA 7Sanofi, Paris, France 8University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA |
||||
|
(410) THROMBOELASTOMETRY (TEG): UTILITY IN DIAGNOSING OF INFECTION IN NEUROSURGERY INTENSIVE CARE UNIT (ICU) AS COMPARED TO ESTABLISHED BIOMARKERS Renu Rani, Deepak Agarwal. AIIMS, New Delhi, India |
|||||
|
(411) FOURTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES Mark T Reding1, Beng Fuh2, Vanessa Salinas3, Maissaa Janbain4. 1University of Minnesota Medical Center, Minneapolis, MN, USA 2East Carolina University, Greenville, NC, USA 3Center for Inherited Blood Disorders, Orange, CA, USA 4Tulane School of Medicine, New Orleans, LA, USA |
||||
|
(412) EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: SUMMARY OF 10 YEARS OF SAFETY DATA ON THROMBOEMBOLIC EVENTS AND THROMBOTIC MICROANGIOPATHY Katayon Sarouei1, Simona Barlera2, Letizia Polito3, Guillermo Tobaruela3, Juliana M.L Biondo1. 1Genentech, Inc., South San Francisco, CA, USA 2Parexel International, Milan, Italy 3F. Hoffmann-La Roche Ltd, Basel, Switzerland |
||||
|
(413) ACQUIRED VON WILLEBRAND SYNDROME IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A FOCUS ON RESPONSE TO TREATMENT WITH IVIG Tanna Tan1, Rajiv K. K. Pruthi2, Aneel A. Ashrani2, Meera Sridharan2. 1Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA 2Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA |
||||
|
(414) TITLE: RECOMBINANT ADAMTS13 REPLACEMENT THERAPY IN A PEDIATRIC PATIENT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA. Katrina` Unpingco1, Michael F. Guerrera2, Zahara Jones1, Alison Matsunaga1. 1Hemophilia and Thrombosis Center UCSF Benioff Children's Hospitals, Oakland -San Francisco, CA, USA 2Hemostasis and Thrombosis Center, Children's National Medical Center, Washington, DC, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(415) TIME TO STABLE THERAPEUTIC ANTICOAGULATION USING WEIGHT-BASED IV HEPARIN DOSING CLINICAL DECISIONS SUPPORT PROGRAM Keri S. Kim, Jean Lee, Miranda Hart, John Garofalo, Jeffrey J. Mucksavage. University of Illinois Chicago College of Pharmacy, Chicago, IL, USA |
||||
|
(416) MONITORING BIVALIRUDIN ANTICOAGULANT EFFECT BY THE ADDITION OF DILUTED THROMBIN TIME COMPARED TO ACTIVATED PARTIAL THROMBOPLASTIN TIME ALONE Vadim Kostousov, Karen Bruzdoski, Jun Teruya. Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA |
||||
|
(417) COMPARATIVE PROTAMINE SULFATE AND HEPA-REMOVE NEUTRALIZATION STUDIES IN POTENCY ADJUSTED PORCINE AND BOVINE HEPARIN Emily Krupa, Debra Hoppensteadt-Moorman, Walter Jeske, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(418) THE RISK OF RECURRENT VENOUS THROMBOEMBOLSIM AND HEMORRHAGE IN THE POSTPARTUM PATIENT REQURING ANTICOAGULATION Thomas Kiebalo1,2, Ann Malinowski1,4, Jose Carvalho1,5, Nadine Shehata1,2,3. 1Mount Sinai Hospital, Toronto, ON, Canada 2Department of Medicine, University of Toronto, Toronto, ON, Canada 3Department of Hematology, University of Toronto, Toronto, ON, Canada 4Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada 5Department of Anesthesiology, University of Toronto, Toronto, ON, Canada |
||||
|
(419) NOVEL THROMBOPHILIA- PROTHROMBIN BELGRADE VARIANT IN A MEXICAN FAMILY Natalie/A Montanez1,3, Miguel/A Escobar1,2,3. 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA 3Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA |
||||
|
(420) "THERE IS SO MUCH POWER IN JUST BELIEVING SOMEONE": UNDERSTANDING THE LIVED EXPERIENCES OF WOMEN WITH HEAVY VAGINAL BLOOD LOSS Fartoon M Siad1, Andrea Lausman2, Carolyn Snider3, Martina Trinkaus1, Filomena Meffe2, Michelle Sholzberg 1,4. 1Department of Medicine, University of Toronto, Toronto, ON, Canada 2Department of Obstetrics and Gynecology, Toronto, ON, Canada 3Division of Emergency Medicine, Toronto, ON, Canada 44Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada |
||||